Blutungsrisiko und Blutungsnotfälle unter Rivaroxaban: Periinterventionelles Hämostase management

Hamostaseologie

Volumn 32, Issue 4, 2012, Pages 287-293

  Koscielny, J ^a   Beyer Westendorf, J ^b   Von Heymann, C ^a   Braun, J ^c   Klamroth, R ^d   Lindhoff Last, E ^e   Tiede, A ^f   Spannagl, M ^g  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Innere Medizin I   (Germany)

^d VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Anticoagulants; Bleeding risk; Bleedings; Management of haemostasis; Perinterventional management; Rivaroxaban

Indexed keywords

RIVAROXABAN; TRANEXAMIC ACID; ANTICOAGULANT AGENT; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG MONITORING; ELECTIVE SURGERY; HEMODYNAMICS; HEMOSTASIS; HOMEOSTASIS; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER FUNCTION; LONG TERM CARE; THERAPY EFFECT; THROMBOPLASTIN TIME; CHEMICALLY INDUCED DISORDER; DRUG CONTRAINDICATION; DRUG EFFECT; HUMAN; POSTOPERATIVE HEMORRHAGE;

ANTICOAGULANTS; HEMOSTASIS; HUMANS; MORPHOLINES; POSTOPERATIVE HEMORRHAGE; THIOPHENES;

EID: 84873575289     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/ha-2012030001     Document Type: Article

References (28)

1. ® (rivaroxaban) Summary of Product Characteristics. 2011. www.xarelto.com/html/downloads/ Xarelto_Summary_ of_Product_Characteristics_Dec2011.pdf (accessed on 9 January 2012).
2. Perzborn E, Roehrig S, Straub A et al. The discovery and development of rivaroxaban, an oral, direct Factor Xa inhibitor. Nat. Rev. Drug Discov 2011; 10: 61-75.
3. Lang D, Freudenberger C, Weinz C. In vitro metabolism of rivaroxaban - an oral, direct Factor Xa inhibitor - in liver microsomes and hepatocytes of rat, dog and man. Drug Metab Dispos 2009; 37: 1046-1055.
4. Weinz C, Schwarz T, Kubitza D et al. Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans. Drug Metab Dispos 2009; 37:1056-1064.
5. Harbrecht U. Old and new anticoagulants. Hämostaseologie 2011; 31: 21-27.
6. Turpie AGG, Lassen MR, Eriksson BI et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105: 444-453.
7. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
8. Mega JL, Braunwald E, Mohanavelu S et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374: 29-38.
9. Patel MR, Mahaffey KW, Garg J et al. Prevention of stroke and systemic embolism using the oral direct Factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: the ROCKET AF trial. N Engl J Med 2011; 365: 883-891.
10. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2011; 366: 9-19.
11. The EINSTEIN-PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med 2012; 366: 1287 - 1297.
12. Lindhoff-Last E, Samama MM, Ortel TL et al. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010; 32: 673-679.
13. Kubitza D, Becka M, Wensing G et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-880.
14. Mueck W, Eriksson BI, Bauer KA et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients underfügbaren-going major orthopaedic surgery. Clin Pharmacokinet 2008; 47: 203-216.
15. Kubitza D, Becka M, Voith B et al. Safety. Pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421.
16. Lindhoff-Last E, Samama MM, Ortel TL et al. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010; 32: 673-679.
17. Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost 2011; 106: 1-9.
18. Haas S, Turpie A, Lassen M et al. Prothrombin time and bleeding events in patients undergoing total hip or knee replacement surgery receiving 10 mg rivaroxaban. ASH 2009, Poster Session: Antithrombotic Therapy Poster II, 2099.
19. Samama MM, Contant G, Spiro T et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-387.
20. Mani H, Rohde G, Stratmann G et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 2012; 108: 191-198.
21. Mueck W, Lensing A, Agnelli G et al. Rivaroxaban: Population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 10: 675-686.
22. Fachinformation Xarelto. Rote Liste 2012.
23. Van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
24. McCormack PL. Tranexamic acid: A review of its use in the treatment of hyperfibrinolysis. Drugs 2012; 72: 585 - 617.
25. ®. Rote Liste (Dezember 2010).
26. Spannagl M, Koscielny J, Kiesewetter H. Prokoagulatoren. In: Aktuelle Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten der Bundesärztekammer 2009: 153-154.
27. Guyatt GH, Akl EA, Crowther M, Gutterman DD for the American College of Chest Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians. Chest 2012; 141: 7S-47S.
28. Marlu R, Hodaj E, Paris A et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. Thromb Haemost 2012; 108: 217-224